London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
£25m market cap?! This is below the valuation level of a number of startups with shorter track record and IP that hasn't been developed to the same degree as that of SCLP! However, they may have impressive management who are keen to lead an IP-based venture to commercial success and are skilled in attracting and keeping engaged different types of investors.
Now, it would be easy to blame the market and yes, there are a lot of investors with a short term focus.
But, on the other hand, Scancell hardly gives a sense of continuity and follow up on its own RNS. What's happening with SCIB1 after the February announcement? Could we ask an indication of next steps and timing? How is the sourcing of funding with respect to the Covid-19 vaccine coming along? Any progress with respect to the team-ups with third parties that have been announced? It is not just once or twice: by throwing RNS that enthuse the market for a short while and then either not following up or doing so after a long time, the company can only encourage short-termism among investors that are drawn to the share.
We are not backing a group of academics who are keen to publish papers on their area of expertise - such contributions are essential too in medical fields or biotech and wouldn't wish to underestimate their importance. However, those more interested in academic research or not keen to be more communicative, should stay in research rather than be part of the management team of a listed company. Or maybe they can change their style of management and engage more with the market. After all, they do have the duty to report to shareholders on a reasonably regular basis. Maybe the above would be topical to raise at the next AGM?
Michaelhighbar
Some good points well made - thanks
Seconded, great post Michaelhighbar.
Yes Michaelhighbar a well thought out and presented post.
I would love it if they changed their style of management and engage more with the market but I am not optimistic about that happening.When Vulpes came in board that seemed the ideal opportunity to change direction but that has not happened.
At AGMs I have found them very defensive but love in hope that they will reverse that trend however this years affair is likely imo to be a Virtual one so they may get away with their preferred modus operandi.
But very welcome comments and thanks for putting them forward.
""" We are not backing a group of academics who are keen to publish papers on their area of expertise - such contributions are essential too in medical fields or biotech and wouldn't wish to underestimate their importance. However, those more interested in academic research or not keen to be more communicative, should stay in research rather than be part of the management team of a listed company. """
who are you referring to ? Micheal ..
At AGMs I have found them very defensive...........
probably because all you ask them about is Funding ....
"previous discussions in history" .... result .. Ivy expects to receive an answer that the BOD cannot Give ...
Bermuda ref "good points"
What are they ? ..
If Scancell were to employ a publicist some would say they are wasting precious resources; others would speculate the publicity was in preparation for fund-raising and others might just wonder what has driven the change in approach.
They cannot satisfy everybody all the time. Scancell need the attention of a large Pharma company - if and when this happens shareholders will be rewarded. Attracting investors on PR fluff is not sustainable if they buy on the open market, especially when a company does placings as opposed to open offers. If you feel that placings are done at too low a price then register your interest to participate with the companies Broker.
Inanaco
It's public info who's on the board and, in particular, who the executives are.
The aim of my post was to see to what extent other investors had similar thoughts about issues related to the overall management style in order to bring them up at the AGM in a concerted way. There seem to be a decent number of PIs who have similar thoughts. In any case, even if people keep quiet in here, the market is speaking so loudly that is impossible to turn a deaf ear. So you may also want to question the market why it values the company at this ludicrous level.
By the way, there is no need for PR to address the issues raised in my post which are mostly about susbtance and less about form. You only need a good PR if you are not delivering the right results.
Best,
MHB
yes but you have not answered the question
""However, those more interested in academic research or not keen to be more communicative, should stay in research rather than be part of the management team of a listed company. """
who are you talking about ?
Inanaco,
Over the years, I have posted several times that Scancell need to improve on investor relations and have previously suggested that they hire a specialist to look after their IR on a part time basis. I'll happily go over Michael's post again and pick out the bits I most agree with but what's the point?
"""The aim of my post was to see to what extent other investors had similar thoughts about issues related to the overall management style in order to bring them up at the AGM in a concerted way. """
that will never work from just posters on here, for a start quite a few of the questions you would like answered are price sensitive or locked in via Non Disclosure ...........
you then posted
"""So you may also want to question the market why it values the company at this ludicrous level""
and how do we do that exactly ??
intrigued ... Bermuda ... indeed the recent PR inc National TV resulted in ? probably more confusion because now the GOV has been put under the spot light via the lack of Funding ...
I have said this many times ...
PR to investors . ? = Dr Kim .. do we need that constant Grandstanding which then flops
Total lie as usual.
At the AGMs I have attended I have never asked a question about funding out of a total of 4 questions asked.
How you are supposed to know whether the BoD were defensive or not I really don’t know. I am referring to 2017 and 2018 which I attended and you did not as you could not afford the petrol money.
Bit like you being so defensive now.
You get a new poster with no axe to grind which gets 11 recs so chimes with a few folk but you still find fault and the fact you don’t think SCLP needs to improve SH communication just shows how out of touch you are
i can string the entire thread into one part ............ its called the Puzzle .. and folks keep trying to blame different areas but cant quite manage to or don't know how to express it .... they want more but the constraints of PLC's ... dont allow that
and its this bit
""""why it values the company at this ludicrous level""""
Nobody can understand it ... and that is why folks get frustrated
But Ivy ...
your post only got 1 rec ?
Inanaco, I have answered but you obviously didn't like my answer :-)
LOL
not at all ... just trying to define what you actually mean ...
you describe somebody that should not be on the BOD ... but you will not tell us ...
and you have suggested we ask the market
but explained no route ?
I would hope that the large Institutional Investors and the likes of Vulpes hold the Scancell board to account.
If the company was being run as a LifeStyle company the large investor would vote with their feet.
When we read of the large Bio / Pharma deals we don't always know how many years it has taken to hone the scientific to produce the Data that won them that deal. We just see a headline.
Scancell and others have been placed in hibernation due to the pandemic but Lindy and team have stepped up to produce a 2nd Gen Vaccine and for that we hear private investor grumble "why do I not know whats going on".
Well you do know as much as the company can tell you or do we need to know when they're having a brew !!
Chester.
Inanaco -
Whether you agree with it or not, it's important that any listed company handles investor relations well. You quote an extreme, Dr. Kim from Inovio. IMO that's not good IR - it's hype. Traders will love it but serious investors can tell the difference a mile off.
If you want to attract and more importantly retain long term investors then you have to communicate well with them and keep them engaged. That applies to retail and institutional investors alike. If a large or reasonably large portion of your shares are held by institutions then you can afford to devote less time and effort to your retail investors. However, if not..........................
Ivy
i listened to the transcripts .. so I don't need to attend AGM as well, its a 4/5 hr drive from here, and Lindy will communicate with me on the heavy stuff .. no idea How the "petrol issue" has got into your head .. for a Start i drive Diesel BMW's
I guess in my view, this is where a good communications manager comes into their own. They have some great material, but it is not being "placed" in the media.
All the questions I've seen on "where are we" could be answered by a (twice)* monthly video update lodged on the media page. (*I'm not sure about the frequency.)
I believe many start ups have a marketing and/or comms activity.
As for the price, if people are prepared to sell at this level, that is their call.
yes Bermuda .......... but what are you Missing ? what are we missing
what is the piece that will drive the SP ...
after all we have established the market has a problem
hence .................... """"why it values the company at this ludicrous level""""
probably the greatest exponent of PR is Bunsie ...
and he don't know either ....
One thing Scancell is very open about is the science. It is explained very well on their website and also in the Trinity Delta reports. You get enough detail on how the science works and it is explained in ways that make it fairly easy to understand.
However, I suspect it goes over the heads of many recent investors, especially the short term traders. In fact, many will just buy in expecting things to happen in a short timescale. An example of this is the Covidity announcement.
Many of the LTHs also originally bought in on the expectation of fairly rapid gains.
I get the impression that Lindy is a perfectionist. She will not release a product into development until she has done everything possible to ensure its success. So, for instance, on Covidity, despite the obvious urgency she will still try to cover all bases. This in itself will lengthen the timescales.
So an mcap of £27 million can be looked at in 2 very different ways
1) A struggling biotech that is simply not producing anything of worth
2) A potential cure to many hard-to-treat cancers
The scientific community tends towards 2). Evidence the long list of professors who want to be in on the act.
S
As time goes by
Ignore the last 2 lines of my post LOL